FibroGen Q2 2024 GAAP EPS $(0.16) Beats $(0.26) Estimate, Sales $50.641M Beat $34.661M Estimate
Author: Benzinga Newsdesk | August 06, 2024 04:43pm
FibroGen (NASDAQ:
FGEN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.26) by 38.46 percent. This is a 82.22 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $50.641 million which beat the analyst consensus estimate of $34.661 million by 46.11 percent. This is a 14.26 percent increase over sales of $44.319 million the same period last year.
Posted In: FGEN